fotoknips-shutterstock-com-1
fotoknips / Shutterstock.com
8 October 2015PharmaNatalia Wegner-Cribbs and Daniel Wise

A clearer picture for SPCs?

On October 6, the Court of Justice of the European Union (CJEU) delivered its judgment in case C-471/14. It clarified that the term of a supplementary protection certificate (SPC) is determined with reference to the date on which a marketing authorisation is notified to that applicant. This means that in many cases SPC owners that do not already benefit from the maximum five-year term will get some additional term for their products, although it remains to be seen how and to what extent the judgment will be implemented from a practical point of view by the various national patent offices. The judgment may also have implications for aspects of SPC law other than the SPC term, on which the CJEU did not provide any guidance.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
10 September 2026   Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.
Pharma
7 September 2026   A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.
Pharma
27 August 2026   Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.